β受体阻滞剂治疗婴儿血管瘤的研究进展  

Research progress in the treatment of infantile hemangioma with β blockers

作　　者：张敏[1] 李玲(综述)[1] 常明泉(审校)[2] ZHANG Min;LI Ling;CHANG Mingquan(Department of Pharmacy,The People′s Hospital of Maojian,Shiyan,Hubei 442012,China;Department of Pharmacy,Taihe Hospital Affiliated to Hubei University of Medicine,Shiyan,Hubei 442000,China)

机构地区：[1]十堰市茅箭区人民医院药剂科,湖北十堰442012 [2]湖北医药学院附属太和医院药剂科,湖北十堰442000

出　　处：《现代医药卫生》2023年第6期1015-1018,共4页Journal of Modern Medicine & Health

基　　金：湖北省科技进步奖励项目(2019J-244-2-086-068);武当特色中药研究湖北省重点实验室项目(2020DFA009);湖北省科技成果(EK2016D150088001938)。

摘　　要：婴儿血管瘤(IH)是一种良性脉管肿瘤,多见于婴幼儿。近年来,国内许多学者在β受体阻滞剂治疗IH的疗效、安全性、作用机制、不良反应方面逐渐形成一些共识。β受体阻滞剂治疗IH时主要从病灶部位、分类、深度及大小等方面综合决定使用药物种类及给药途径,其治疗效果良好、不良反应用可控。该文对β受体阻滞剂在治疗IH方面的临床效果、不良反应及其对策进行了综述。Infantile hemangioma(IH)is a benign vascular tumor,which is common in infants.In recent years,many domestic scholars have gradually formed some consensus on the efficacy,safety,mechanism of action and adverse reactions ofβblockers in the treatment of IH.In the treatment of IH withβblockers,the type and route of administration of drugs are mainly determined from the aspects of the location,classification,depth and size of the lesion.The treatment effect is good and the adverse reactions are controllable.The article reviews the clinical effects,adverse reactions and countermeasures ofβblockers in the treatment of IH.

关 键 词：Β受体阻滞剂 婴儿血管瘤 不良反应 

分 类 号：R729[医药卫生—儿科]